Modular Medical (NASDAQ:MODD) will present research data at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025, in Chicago. The company will showcase a poster (783-P) examining pump delivery of GLP-1R agonist in diet-induced obese mice, comparing pump-delivered exenatide to intermittent semaglutide dosing. The study aims to address GLP-1 therapy challenges, particularly gastrointestinal tolerability issues that often lead to treatment discontinuation. Modular Medical, known for its FDA-cleared patch pump designed for "almost-pumpers," suggests that personalized GLP-1 titration and dosing, including mealtime bolus options, could improve treatment outcomes and patient tolerance. The presentation is scheduled for June 22, 2025, from 12:30 PM to 1:30 PM in the Poster Hall.
Modular Medical (NASDAQ:MODD) presenterà dati di ricerca alle 85esime Sessioni Scientifiche dell'American Diabetes Association, che si terranno dal 20 al 23 giugno 2025 a Chicago. L'azienda esporrà un poster (783-P) che analizza la somministrazione tramite pompa di un agonista GLP-1R in topi obesi indotti da dieta, confrontando l'exenatide somministrato con pompa con la somministrazione intermittente di semaglutide. Lo studio mira a risolvere le problematiche della terapia GLP-1, in particolare i problemi di tollerabilità gastrointestinale che spesso portano alla sospensione del trattamento. Modular Medical, nota per la sua pompa a cerotto approvata dalla FDA e pensata per gli “almost-pumpers”, suggerisce che una titolazione e dosaggio personalizzati del GLP-1, inclusa l'opzione di boli ai pasti, potrebbero migliorare i risultati terapeutici e la tolleranza dei pazienti. La presentazione è prevista per il 22 giugno 2025, dalle 12:30 alle 13:30, nella Poster Hall.
Modular Medical (NASDAQ:MODD) presentará datos de investigación en la 85ª Sesión Científica de la American Diabetes Association, que se llevará a cabo del 20 al 23 de junio de 2025 en Chicago. La compañía mostrará un póster (783-P) que examina la administración mediante bomba de un agonista GLP-1R en ratones obesos inducidos por dieta, comparando la administración de exenatida con bomba frente a la dosificación intermitente de semaglutida. El estudio busca abordar los desafíos de la terapia con GLP-1, especialmente los problemas de tolerabilidad gastrointestinal que a menudo llevan a la interrupción del tratamiento. Modular Medical, conocida por su bomba parche aprobada por la FDA diseñada para los “casi usuarios de bomba”, sugiere que la titulación y dosificación personalizada de GLP-1, incluyendo opciones de bolo en las comidas, podría mejorar los resultados del tratamiento y la tolerancia del paciente. La presentación está programada para el 22 de junio de 2025, de 12:30 p.m. a 1:30 p.m. en el Poster Hall.
Modular Medical(NASDAQ:MODD)는 2025년 6월 20일부터 23일까지 시카고에서 열리는 미국 당뇨병학회(ADA) 제85회 과학 세션에서 연구 데이터를 발표합니다. 회사는 식이 유도 비만 쥐를 대상으로 GLP-1R 작용제의 펌프 투여에 관한 포스터(783-P)를 선보이며, 펌프로 투여한 엑세나타이드와 간헐적 세마글루타이드 투여를 비교합니다. 이 연구는 치료 중단을 초래하는 위장관 내 내약성 문제 등 GLP-1 치료의 어려움을 해결하는 것을 목표로 합니다. FDA 승인 받은 '거의 펌프 사용자'를 위한 패치 펌프로 알려진 Modular Medical은 식사 때 볼루스 옵션을 포함한 맞춤형 GLP-1 용량 조절과 투여가 치료 효과와 환자 내약성을 향상시킬 수 있다고 제안합니다. 발표는 2025년 6월 22일 오후 12시 30분부터 1시 30분까지 포스터 홀에서 진행됩니다.
Modular Medical (NASDAQ:MODD) présentera des données de recherche lors des 85èmes Sessions Scientifiques de l’American Diabetes Association, qui se tiendront du 20 au 23 juin 2025 à Chicago. L’entreprise exposera un poster (783-P) examinant l’administration par pompe d’un agoniste GLP-1R chez des souris obèses induites par un régime alimentaire, comparant l’exénatide administré par pompe à une dose intermittente de sémaglutide. L’étude vise à relever les défis de la thérapie GLP-1, notamment les problèmes de tolérance gastro-intestinale qui conduisent souvent à l’arrêt du traitement. Modular Medical, connue pour sa pompe patch approuvée par la FDA, conçue pour les « presque utilisateurs de pompe », suggère qu’une titration et un dosage personnalisés du GLP-1, incluant des options de bolus aux repas, pourraient améliorer les résultats du traitement et la tolérance des patients. La présentation est prévue le 22 juin 2025 de 12h30 à 13h30 dans le Poster Hall.
Modular Medical (NASDAQ:MODD) wird Forschungsergebnisse auf der 85. Wissenschaftlichen Tagung der American Diabetes Association präsentieren, die vom 20. bis 23. Juni 2025 in Chicago stattfindet. Das Unternehmen wird ein Poster (783-P) vorstellen, das die Pumpenabgabe eines GLP-1R-Agonisten bei diätinduzierten adipösen Mäusen untersucht und die Pumpenverabreichung von Exenatid mit der intermittierenden Gabe von Semaglutid vergleicht. Die Studie zielt darauf ab, Herausforderungen der GLP-1-Therapie zu adressieren, insbesondere gastrointestinale Verträglichkeitsprobleme, die häufig zum Abbruch der Behandlung führen. Modular Medical, bekannt für seine von der FDA zugelassene Patch-Pumpe, die für „Fast-Pump-Anwender“ entwickelt wurde, schlägt vor, dass eine personalisierte GLP-1-Titration und Dosierung, einschließlich Bolusoptionen zu den Mahlzeiten, die Behandlungsergebnisse und die Verträglichkeit für Patienten verbessern könnten. Die Präsentation ist für den 22. Juni 2025 von 12:30 bis 13:30 Uhr in der Posterhalle geplant.
Positive
None.
Negative
None.
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, is pleased to announce its participation in the American Diabetes Association ("ADA") 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
The Company will feature a poster, number 783-P, titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse," to be presented by David Maggs, MD, FRCP during the General Poster Session on Sunday, June 22, 2025, from 12:30pm to 1:30pm in the Poster Hall. The presentation will highlight data from an exploratory study evaluating the effects of pump-delivery of a short-acting GLP-1RA on weight, food intake, and glucose tolerance in a diet-induced obese ("DIO") mouse.
"We are excited to share our findings from this novel study in the DIO mouse comparing the pump delivery of exenatide to intermittent dosing of semaglutide," said Jeb Besser, CEO of Modular Medical. "Given the high rate of gastrointestinal tolerability challenges and resultant discontinuation that is characteristic of GLP-1 therapy, we believe that a personalized approach to GLP-1 titration and dosing, including a mealtime bolus option, would give patients an opportunity to reach their treatment goals, while experiencing easier therapy initiation and a more tolerable maintenance regimen."
The ADA 85th Scientific Sessions is the world's largest diabetes conference, bringing together over 11,000 physicians, scientists, and healthcare professionals to explore cutting-edge advancements in diabetes research, treatment, and care. Modular Medical's participation underscores its commitment to driving innovation in diabetes therapies and improving patient outcomes.
CONTACT:
Jeb Besser Chief Executive Officer Modular Medical, Inc. +1 (617) 399-1741
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its insulin pump. More information is available at https://modular-medical.com.
About the American Diabetes Association Scientific Sessions
The American Diabetes Association Scientific Sessions is the premier global meeting for diabetes research, prevention, and care. Held annually, it offers a platform for sharing groundbreaking research and fostering collaboration among leading experts in the field. For more information, visit https://professional.diabetes.org/scientific-sessions.
What will Modular Medical present at the ADA 85th Scientific Sessions in 2025?
Modular Medical will present poster 783-P, studying pump-delivered subcutaneous GLP-1R agonist effects in diet-induced obese mice, comparing exenatide pump delivery to intermittent semaglutide dosing.
When and where will MODD present their research at ADA 2025?
The presentation will take place on Sunday, June 22, 2025, from 12:30 PM to 1:30 PM in the Poster Hall at McCormick Place Convention Center in Chicago.
What is the main focus of Modular Medical's MODD GLP-1 pump delivery study?
The study focuses on evaluating the effects of pump-delivery of short-acting GLP-1RA on weight, food intake, and glucose tolerance, aiming to address gastrointestinal tolerability challenges in GLP-1 therapy.
What is Modular Medical's MODD main product?
Modular Medical has developed the first FDA-cleared patch pump specifically designed for 'almost-pumpers,' featuring a user-friendly and affordable design.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
